Literature DB >> 29718081

Neuropsychological Practice in the Oncology Setting.

Kyle R Noll1, Mariana E Bradshaw1, Jennie Rexer1, Jeffrey S Wefel1.   

Abstract

Oncology has experienced positive shifts in survival curves for many cancers largely due to the development of earlier diagnostics and better therapeutics. This has increased the visibility and need for survivorship services, including clinical neuropsychology. Patients with cancer frequently experience cognitive dysfunction related to the presence of cancer itself and treatment neurotoxicity. These cognitive difficulties can profoundly impact patient functioning and autonomy with accompanying declines in quality of life. Clinical neuropsychologists are uniquely positioned to evaluate the cognitive and affective sequelae of cancer and treatment and provide interventions and recommendations that can benefit well-being and potentially alter the disease course. Despite increasing recognition of the importance of neuropsychological issues to cancer survivorship, many neuropsychologists have limited training and guidance regarding navigating and implementing services within the oncology setting. This article provides the basic rationale for neuropsychological practice and research activities in oncology, as well as the experience of the Section of Neuropsychology at The University of Texas MD Anderson Cancer Center.

Entities:  

Mesh:

Year:  2018        PMID: 29718081      PMCID: PMC5920294          DOI: 10.1093/arclin/acx131

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  44 in total

Review 1.  Neuroepidemiology of cancer and treatment-related neurocognitive dysfunction in adult-onset cancer patients and survivors.

Authors:  P Jean-Pierre; B C McDonald
Journal:  Handb Clin Neurol       Date:  2016

Review 2.  Neurological complications of radiotherapy and chemotherapy.

Authors:  F Keime-Guibert; M Napolitano; J Y Delattre
Journal:  J Neurol       Date:  1998-11       Impact factor: 4.849

3.  Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.

Authors:  Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie Holland
Journal:  J Am Geriatr Soc       Date:  2006-06       Impact factor: 5.562

Review 4.  Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Authors:  Jaishri O Blakeley; Stephen Joel Coons; John R Corboy; Nancy Kline Leidy; Tito R Mendoza; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 6.  Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy.

Authors:  J R Crossen; D Garwood; E Glatstein; E A Neuwelt
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

7.  Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.

Authors:  Terri S Armstrong; Jeffrey S Wefel; Meihua Wang; Mark R Gilbert; Minhee Won; Andrew Bottomley; Tito R Mendoza; Corneel Coens; Maria Werner-Wasik; David G Brachman; Ali K Choucair; Minesh Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  Four-week prevalence of mental disorders in patients with cancer across major tumor entities.

Authors:  Anja Mehnert; Elmar Brähler; Hermann Faller; Martin Härter; Monika Keller; Holger Schulz; Karl Wegscheider; Joachim Weis; Anna Boehncke; Bianca Hund; Katrin Reuter; Matthias Richard; Susanne Sehner; Sabine Sommerfeldt; Carina Szalai; Hans-Ulrich Wittchen; Uwe Koch
Journal:  J Clin Oncol       Date:  2014-10-06       Impact factor: 44.544

9.  Exercise Recommendations for Cancer-Related Fatigue, Cognitive Impairment, Sleep problems, Depression, Pain, Anxiety, and Physical Dysfunction: A Review.

Authors:  Karen M Mustian; Lisa K Sprod; Michelle Janelsins; Luke J Peppone; Supriya Mohile
Journal:  Oncol Hematol Rev       Date:  2012

10.  Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection.

Authors:  Kyle R Noll; Catherine Sullaway; Mateo Ziu; Jeffrey S Weinberg; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2014-09-16       Impact factor: 12.300

View more
  4 in total

Review 1.  Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients.

Authors:  Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2019-04-08

Review 2.  Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer.

Authors:  Tomasz M Beer; Neal Shore; Alicia Morgans; Kerri Winters-Stone; Jeffrey S Wefel; Daniel J George
Journal:  BJUI Compass       Date:  2022-08-24

Review 3.  Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?

Authors:  Sanne B Schagen; Andrey S Tsvetkov; Annette Compter; Jeffrey S Wefel
Journal:  Nat Rev Neurol       Date:  2022-02-09       Impact factor: 44.711

Review 4.  Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors.

Authors:  Jeffrey S Wefel; Charles J Ryan; Julie Van; James C Jackson; Alicia K Morgans
Journal:  CNS Drugs       Date:  2022-05-06       Impact factor: 6.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.